Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 4(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01756807Not ApplicableCompleted

EGO-COMBO Angiographic Extension Study

Role: lead

NCT01274234Phase 1Completed

OCT Evaluation of Healing of COMBO Stent

Role: lead

NCT01200056Phase 4Completed

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment

Role: lead

NCT01272895Phase 4Completed

OCT Evaluation of Early Healing of EPC Capturing (GENOUS) Stent (EGO Study)

Role: lead

All 4 trials loaded